Your search for replac returned 582 results

Congenital thrombotic thrombocytopenic purpura is an ADAMTS13 deficiency disorder.

The FDA has approved Kyzatrex (testosterone undecanoate) for the treatment of primary and secondary hypogonadism in adult males.

Tlando is supplied as 112.5mg of testosterone undecanoate capsules.

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.

For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously.

VX-880 is an investigational allogeneic human stem cell-derived islet cell therapy that may restore pancreatic islet cell function.

Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.

The FDA has approved the New Drug Application for Triferic AVNU®.

Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.

According to the results of a recent review, the efficacy of nicotine replacement therapy (NRT) in achieving long-term smoking cessation varies based on NRT delivery method, dosage, and timing of initiation.